Skip navigation
Universidade Federal da Bahia |
Repositório Institucional da UFBA
Use este identificador para citar ou linkar para este item: https://repositorio.ufba.br/handle/ri/13505
Tipo: Artigo de Periódico
Título: Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment
Título(s) alternativo(s): Genetics and Molecular Biology
Autor(es): Giugliani, Roberto
Federhen, Andressa
Rojas, Maria Verônica Muñoz
Acosta, Angelina Xavier
Bonfim, Carmen
Lourenço, Charles Marques
Pimentel, Helena
Autor(es): Giugliani, Roberto
Federhen, Andressa
Rojas, Maria Verônica Muñoz
Acosta, Angelina Xavier
Bonfim, Carmen
Lourenço, Charles Marques
Pimentel, Helena
Abstract: Mucopolysaccharidoses (MPS) are rare genetic diseases caused by the deficiency of one of the lysosomal enzymes involved in the glycosaminoglycan (GAG) breakdown pathway. This metabolic block leads to the accumulation of GAG in various organs and tissues of the affected patients, resulting in a multisystemic clinical picture, sometimes including cognitive impairment. Until the beginning of the XXI century, treatment was mainly supportive. Bone marrow transplantation improved the natural course of the disease in some types of MPS, but the morbidity and mortality restricted its use to selected cases. The identification of the genes involved, the new molecular biology tools and the availability of animal models made it possible to develop specific enzyme replacement therapies (ERT) for these diseases. At present, a great number of Brazilian medical centers from all regions of the country have experience with ERT for MPS I, II, and VI, acquired not only through patient treatment but also in clinical trials. Taking the three types of MPS together, over 200 patients have been treated with ERT in our country. This document summarizes the experience of the professionals involved, along with the data available in the international literature, bringing together and harmonizing the information available on the management of these severe and progressive diseases, thus disclosing new prospects for Brazilian patients affected by these conditions.
Palavras-chave: Mucopolisaccharidoses
Hurler syndrome
Hunter syndrome
Maroteaux-Lamy syndrome
Enzyme replacement therapy
Treatment guidelines
URI: http://repositorio.ufba.br/ri/handle/ri/13505
Data do documento: 2010
Aparece nas coleções:Artigo Publicado em Periódico (Faculdade de Medicina)

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
2010-050.pdf137,05 kBAdobe PDFVisualizar/Abrir
Mostrar registro completo do item Visualizar estatísticas


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.